Dr. Eric Knoche
Dr. Knoche is an Oncologist at the St. Louis VA. He is currently the PI on Propel, Amplitude, and YONSA, and several other non-clinical trial projects. He formerly served as the PI on Talapro-2 and CANOPY
"I have the education background, knowledge base, research training and experience to support clinical trial research. My first experience in clinical trial research was during fellowship training at Washington University School of Medicine. We completed an investigator IND application to the FDA for treatment of Chuvash polycythemia with ruxolitinib. The process introduced me to the critical steps for trial initiation and continuation including protocol development, IRB submission, patient education, patient assessment and data collection. After this, I have continued to participate in clinical research at Washington University as sub-PI for multiple network and industry sponsored trials. At the John Cochran VAMC, I serve as PI for multiple national cooperative group and industry sponsored clinical trials. As section chief of hematology and oncology at the John Cochran VAMC I have a unique opportunity to fulfill my personal objective to improve cancer outcomes for ethnic/racial minorities and the economically disadvantaged. I envision increased clinical trial enrollment opportunities at the John Cochran VAMC as a foundation for realizing this objective. It is my intention to continue to expand our clinical trial platform to increase trial participation. To date, I serve as PI for ten active clinical trials. I strongly believe that this will enhance the quality of care for our patients."
"I have the education background, knowledge base, research training and experience to support clinical trial research. My first experience in clinical trial research was during fellowship training at Washington University School of Medicine. We completed an investigator IND application to the FDA for treatment of Chuvash polycythemia with ruxolitinib. The process introduced me to the critical steps for trial initiation and continuation including protocol development, IRB submission, patient education, patient assessment and data collection. After this, I have continued to participate in clinical research at Washington University as sub-PI for multiple network and industry sponsored trials. At the John Cochran VAMC, I serve as PI for multiple national cooperative group and industry sponsored clinical trials. As section chief of hematology and oncology at the John Cochran VAMC I have a unique opportunity to fulfill my personal objective to improve cancer outcomes for ethnic/racial minorities and the economically disadvantaged. I envision increased clinical trial enrollment opportunities at the John Cochran VAMC as a foundation for realizing this objective. It is my intention to continue to expand our clinical trial platform to increase trial participation. To date, I serve as PI for ten active clinical trials. I strongly believe that this will enhance the quality of care for our patients."